Oxidative Stress Biomarkers in Oncology: Biological Mechanisms, Clinical Utility, and Organizational Considerations.
- 1Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 24 Karłowicza Street, 85-092 Bydgoszcz, Poland.
- 2Department of Organizational Innovation Management, Faculty of Management, Bydgoszcz University of Science and Technology, 7 Professor S. Kaliski Avenue, 85-796 Bydgoszcz, Poland.
Abstract
Oxidative stress is a fundamental driver of carcinogenesis and tumor progression, arising from an imbalance between reactive oxygen or nitrogen species and antioxidant defense mechanisms. This redox disruption contributes to genomic instability, metabolic reprogramming, inflammation, immune modulation, and therapy resistance processes that together influence the biological behavior of cancer. A broad spectrum of oxidative stress biomarkers has been evaluated in oncology, including markers of lipid peroxidation, protein oxidation, DNA oxidation, and enzymatic or non-enzymatic antioxidant systems. This review integrates current mechanistic knowledge of the formation and functional significance of these biomarkers and evaluates clinical evidence regarding their diagnostic, prognostic, and predictive usefulness across multiple cancer types. We examine whether oxidative stress biomarkers could complement established measures of risk and describe treatment-related changes in systemic oxidative status, while distinguishing these potential applications from validated clinical uses. Despite promising findings, biomarker implementation remains limited by analytical variability, lack of standardized reference ranges, and insufficient prospective validation. Beyond biomedical considerations, the review also highlights key organizational and quality-related factors that may influence the integration of oxidative stress biomarkers into clinical practice. These include laboratory quality assurance requirements, methodological standardization, workflow and data management needs, and broader health system implications. By integrating mechanistic, clinical, analytical, and organizational evidence, this review identifies the validation and quality requirements that must be met before oxidative stress biomarkers can inform routine oncology decisions.
Related
- Oxidative Stress in Chronic Rhinosinusitis with Nasal Polyps: Pathophysiological Mechanisms, Biomarkers, and Therapeutic Implications
- Case Report: Synthetic mesh failure and biological mesh salvage in major oncologic abdominal wall reconstruction—a two-case series with technical considerations
- Screening traditional Chinese medicine monomers for premature ovarian insufficiency: from network meta-analysis to the effects of a promising candidate on oxidative stress biomarkers
- Biological and Clinical Applications of Dimethyl Sulfoxide: Evidence and Safety Considerations
- Biomarkers of Individual Health Status Provide a Biological Signature of the Whole Person Living with Chronic Pain
BibTeX
@article{pawlowska2026oxidative,
title = {{Oxidative Stress Biomarkers in Oncology: Biological Mechanisms, Clinical Utility, and Organizational Considerations.}},
author = {Marta Pawłowska and Celestyna Mila-Kierzenkowska and Marek Jóźwiak and Jarosław Nuszkiewicz},
journal = {Antioxidants (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antiox15101341},
url = {https://europepmc.org/article/MED/42939915},
note = {CC BY},
}
RIS
TY - JOUR
TI - Oxidative Stress Biomarkers in Oncology: Biological Mechanisms, Clinical Utility, and Organizational Considerations.
AU - Marta Pawłowska
AU - Celestyna Mila-Kierzenkowska
AU - Marek Jóźwiak
AU - Jarosław Nuszkiewicz
PY - 2026
DA - 2026/10/16
JO - Antioxidants (Basel, Switzerland)
DO - 10.3390/antiox15101341
UR - https://europepmc.org/article/MED/42939915
AB - Oxidative stress is a fundamental driver of carcinogenesis and tumor progression, arising from an imbalance between reactive oxygen or nitrogen species and antioxidant defense mechanisms. This redox disruption contributes to genomic instability, metabolic reprogramming, inflammation, immune modulation, and therapy resistance processes that together influence the biological behavior of cancer. A broad spectrum of oxidative stress biomarkers has been evaluated in oncology, including markers of lipid peroxidation, protein oxidation, DNA oxidation, and enzymatic or non-enzymatic antioxidant systems. This review integrates current mechanistic knowledge of the formation and functional significance of these biomarkers and evaluates clinical evidence regarding their diagnostic, prognostic, and predictive usefulness across multiple cancer types. We examine whether oxidative stress biomarkers could complement established measures of risk and describe treatment-related changes in systemic oxidative status, while distinguishing these potential applications from validated clinical uses. Despite promising findings, biomarker implementation remains limited by analytical variability, lack of standardized reference ranges, and insufficient prospective validation. Beyond biomedical considerations, the review also highlights key organizational and quality-related factors that may influence the integration of oxidative stress biomarkers into clinical practice. These include laboratory quality assurance requirements, methodological standardization, workflow and data management needs, and broader health system implications. By integrating mechanistic, clinical, analytical, and organizational evidence, this review identifies the validation and quality requirements that must be met before oxidative stress biomarkers can inform routine oncology decisions.
SN - 2076-3921
ER -